PMID- 31651105
OWN - NLM
STAT- MEDLINE
DCOM- 20200916
LR  - 20221207
IS  - 2045-7634 (Electronic)
IS  - 2045-7634 (Linking)
VI  - 8
IP  - 18
DP  - 2019 Dec
TI  - Targeted RNA-sequencing assays: a step forward compared to FISH and IHC 
      techniques?
PG  - 7556-7566
LID - 10.1002/cam4.2599 [doi]
AB  - INTRODUCTION: ALK and ROS1 rearrangements are molecular targets of several 
      tyrosine kinase inhibitors. RNA-sequencing approaches are regarded as the new 
      standard for fusion gene detection, representing an alternative to standard 
      immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) 
      techniques. PATIENTS AND METHODS: We aimed to compare two recent amplicon-based 
      RNA-sequencing techniques: FusionPlex((R)) Alk Ret Ros1 v2 Kit (Archer((R)) ) with 
      FHS-003Z-12-Human Lung Cancer Panel (Qiagen((R)) ) and assessed the accuracy of the 
      data for therapy management. Thirty-seven formalin-fixed paraffin-embedded 
      non-small cell carcinoma (NSCC) lesions initially explored by IHC and FISH were 
      selected for RNA-sequencing analysis. RESULTS: Qiagen((R)) and Archer((R)) kits 
      produced similar results and correctly identified 85.1% (23/27) and 81.5% (22/27) 
      of IHC/FISH ALK- and ROS1-positive samples, respectively, and 100% (6/6) of the 
      negative samples. With regard to the ambiguous IHC-positive/FISH-negative cases, 
      RNA-sequencing confirmed 75% (3/4) of the FISH conclusion. Although not 
      statistically significant, patients with common EML4-ALK variants presented 
      shorter overall survival and progression-free survival compared with patients 
      harboring rare variants. CONCLUSION: Our findings assessed the implementation of 
      RNA-sequencing approaches to explore ALK and ROS1 rearrangements from 
      formalin-fixed paraffin-embedded samples. We highlighted the similarities between 
      Qiagen((R)) and Archer((R)) kits in terms of handling time, cost, and outcomes. We 
      confirmed the feasibility of molecular testing in routine organization and its 
      possible use not only as an alternative for standard IHC and FISH techniques, but 
      as a supplementary technique helping to classify discrepant cases.
CI  - (c) 2019 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.
FAU - Tachon, Gaelle
AU  - Tachon G
AUID- ORCID: 0000-0002-0391-7143
AD  - Laboratoire de Neurosciences Experimentales et Cliniques, Inserm U1084, Poitiers, 
      France.
AD  - Universite de Poitiers, Poitiers, France.
AD  - Laboratoire de Cancerologie Biologique, CHU de Poitiers, Poitiers, France.
FAU - Cortes, Ulrich
AU  - Cortes U
AD  - Laboratoire de Cancerologie Biologique, CHU de Poitiers, Poitiers, France.
FAU - Richard, Sophie
AU  - Richard S
AD  - Universite de Poitiers, Poitiers, France.
AD  - Service d'Anatomo-Cytopathologie, CHU de Poitiers, Poitiers, France.
FAU - Martin, Sebastien
AU  - Martin S
AD  - Laboratoire de Cancerologie Biologique, CHU de Poitiers, Poitiers, France.
FAU - Milin, Serge
AU  - Milin S
AD  - Service d'Anatomo-Cytopathologie, CHU de Poitiers, Poitiers, France.
FAU - Evrard, Camille
AU  - Evrard C
AD  - Service d'Oncologie, CHU de Poitiers, Poitiers, France.
FAU - Lamour, Corinne
AU  - Lamour C
AD  - Service d'Oncologie, CHU de Poitiers, Poitiers, France.
FAU - Karayan-Tapon, Lucie
AU  - Karayan-Tapon L
AD  - Laboratoire de Neurosciences Experimentales et Cliniques, Inserm U1084, Poitiers, 
      France.
AD  - Universite de Poitiers, Poitiers, France.
AD  - Laboratoire de Cancerologie Biologique, CHU de Poitiers, Poitiers, France.
LA  - eng
GR  - Institut National Du Cancer/International
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20191025
PL  - United States
TA  - Cancer Med
JT  - Cancer medicine
JID - 101595310
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (Oncogene Proteins, Fusion)
RN  - 0 (Proto-Oncogene Proteins)
RN  - EC 2.7.10.1 (ALK protein, human)
RN  - EC 2.7.10.1 (Anaplastic Lymphoma Kinase)
RN  - EC 2.7.10.1 (Protein-Tyrosine Kinases)
RN  - EC 2.7.10.1 (ROS1 protein, human)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Anaplastic Lymphoma Kinase/genetics
MH  - Biomarkers, Tumor
MH  - Biopsy
MH  - Carcinoma, Non-Small-Cell Lung/genetics
MH  - Female
MH  - High-Throughput Nucleotide Sequencing
MH  - Humans
MH  - Immunohistochemistry
MH  - In Situ Hybridization, Fluorescence
MH  - Lung Neoplasms/genetics
MH  - Male
MH  - Middle Aged
MH  - Oncogene Proteins, Fusion
MH  - Protein-Tyrosine Kinases/genetics
MH  - Proto-Oncogene Proteins/genetics
MH  - Sequence Analysis, RNA/*methods/standards
MH  - Exome Sequencing
PMC - PMC6912030
OTO - NOTNLM
OT  - cancer genetics
OT  - lung cancer
OT  - medical genetics
OT  - next-generation sequencing
COIS- None declared.
EDAT- 2019/10/28 06:00
MHDA- 2020/09/17 06:00
PMCR- 2019/10/25
CRDT- 2019/10/26 06:00
PHST- 2019/06/21 00:00 [received]
PHST- 2019/09/20 00:00 [revised]
PHST- 2019/09/28 00:00 [accepted]
PHST- 2019/10/28 06:00 [pubmed]
PHST- 2020/09/17 06:00 [medline]
PHST- 2019/10/26 06:00 [entrez]
PHST- 2019/10/25 00:00 [pmc-release]
AID - CAM42599 [pii]
AID - 10.1002/cam4.2599 [doi]
PST - ppublish
SO  - Cancer Med. 2019 Dec;8(18):7556-7566. doi: 10.1002/cam4.2599. Epub 2019 Oct 25.